Matinas Biopharma Holdings, Inc.

MTNB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 79.9%, free cash flow grew 9.15% and total debt fell 54.5%, each against the same quarter a year earlier.

2.37 0.05 −2.07%
Market cap
$2.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
1/9
Altman Z
−11.93
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
0.85 1.32 2.79 3.78
Net Debt/EBITDA
0.52 1.31 2.69 3.73
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(4.30) (3.75) (4.09) (3.18)
Book value per Share
4.21 7.07 13.23 17.82
Free Cash Flow
(1.84) (1.60) (1.49) (1.15)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026